

E•QUAL

EMERGENCY
QUALITY
NETWORK

How to Apply for Buprenorphine Waiver Notification of Intent (NOI)

Presenter



Kathryn Hawk, MD, MHS

- I have received research funding from
 - ▶ NIDA
 - ▶ FDA
 - ▶ Foundation for Opioid Response

- No disclosures to report

Key highlights:

- As of 4/28/21 the Health and Human Services guideline exempt clinicians who will prescribe buprenorphine to fewer than 30 patients at a time from completing the 8-hour DATA 2000 training.
 - ▶ These patients are counted against the provider limit until they are transitioned to a community provider or 30 days from the last prescription if not transitioned.
 - ▶ You still need to apply for the waiver to prescribe buprenorphine but no longer need the waiver training to apply for a 30-patient limit.
- Residents practicing under a training license are not yet eligible for the application for the Notice of Intent.
 - ▶ The X waiver is assigned to an independent entity and requires a valid DEA registration and independent state medical license. The facility training license does not qualify at this time.
 - ▶ These guidelines are directed for independent practitioners. Residents who possess an independent DEA registration and State License are of course eligible.

How to submit the Buprenorphine Waiver Notification

- Step 1. Go to the following link: [SAMHSA DATA Waiver](#)
- Step 2. Fill in next page with DEA number and state license number.
- Step 3. Choose to only apply for the 30-patient level. Under the notice of intent, you are only able to apply for the 30-patient level.

New Applicant Eligible For Waiver Level 30 or 100

Based on the credentials entered, you appear to be a new applicant. If this is not the case and you have previously submitted a waiver application, please recheck your data and resubmit so that we can link your new activity to your existing account. If you need further assistance, please contact our help desk at 866-BUP-CSAT (866-287-2728). You can also email us at infobuprenorphine@samhsa.hhs.gov.

Starting at the 100-Patient Level

New legislation makes it possible for practitioners to apply for a waiver at the 100-patient level if they meet the following condition(s):

- No Yes I am board certified in addiction medicine or addiction psychiatry by the American Board of Preventive Medicine or the American Board of Psychiatry and Neurology.
- OR
- No Yes I provide medication-assisted treatment with covered medications (as such terms are defined under 42 C.F.R. § 8.2) in a qualified practice setting as described under 42 C.F.R. § 8.615.

I wish to apply for the 30-patient level with training.

I wish to apply for the 30-patient level with exemption (no training required).

You are applying for the 30-patient level at this time. Press the Next button to begin your application.

Next

How to submit the Buprenorphine Waiver Notification

New Notification - an initial notification for a waiver submitted for the purpose of obtaining an identification number from DEA for inclusion in the registration under 21 USC § 823(f).

***New Notification 100** - an initial notification for a waiver

New Notification, with the intent to immediately facilitate treatment of an individual (one) patient - an initial notification submitted for the purpose described above, with the additional purpose of notifying the Secretary and the Attorney General of the intent to provide immediate opiate addiction treatment for an individual (one) patient pending processing of this waiver notification.

Second Notification - For physicians who submitted a new notification not less than one year ago and intend and need to treat up to 100 patients. (See Office of National Drug Control Policy Reauthorization Act of 2006.)

6. PURPOSE OF NOTIFICATION

- New Notification to treat up to 30 patients
- Second notification of need and intent to treat up to 100 patients
- New Notification, with the intent to immediately facilitate treatment of an individual (one) patient
- New notification to treat up to 100 patients*

*NOTE: In order to treat up to 100 patients in the first year, practitioners must either hold additional credentialing as defined under 42 C.F.R. § 8.2, or provide medication-assisted treatment with covered medications (as such terms are defined under 42 C.F.R. § 8.2) in a qualified practice setting as described under 42 C.F.R. § 8.615.

7. CERTIFICATION OF USE OF NARCOTIC DRUGS UNDER THIS NOTIFICATION

- When providing maintenance or detoxification treatment, I certify that I will only use Schedule III, IV, or V drugs or combinations of drugs that have been approved by the FDA for use in maintenance or detoxification treatment and that have not been the subject of an adverse determination.

- Step 4. Under section 8, click the “practice guideline exemption” box (in red) or enter the details of your DATA 2000 training course (if taken)

8. CERTIFICATION OF QUALIFYING CRITERIA

I certify that I meet at least one of the following criteria and am therefore a qualifying physician (Check and provide copies of documentation for all that apply):

SAMHSA/HHS Buprenorphine practice guideline exemption (April 2021). These practice guidelines exempt covered practitioners licensed under state law, and who possess a valid DEA registration, from certification requirements related to training, counseling, and other ancillary services (i.e., direct provision of or referral to psychosocial services).

This exemption only applies to those treating up to 30 patients. Time spent practicing under this exemption will not qualify the practitioner for a higher patient limit.

- Subspecialty board certification in Addiction Psychiatry or Addiction Medicine from the American Board of Medical Specialties
- Addiction certification or board certification from the American Society of Addiction Medicine or American Board of Addiction Medicine
- Subspecialty board certification in Addiction Medicine from the American Osteopathic Association

Completion of not less than eight hours of training for the treatment and management of opioid-dependent patients that included training on the following topics: opioid maintenance and detoxification; appropriate clinical use of all drugs approved by the Food and Drug Administration for the treatment of opioid use disorder; initial and periodic patient assessments (including substance use monitoring); individualized treatment planning, overdose reversal, and relapse prevention; counseling and recovery support services; staffing roles and considerations; and diversion control; and that was provided by the following organization(s):

- American Society of Addiction Medicine (ASAM)
- American Academy of Addiction Psychiatry (AAAP)
- American Medical Association (AMA)
- American Osteopathic Association (AOA)/American Osteopathic Academy of Addiction Medicine (AOAAM)
- American Psychiatric Association (APA)
- SAMHSA Providers' Clinical Support System (PCSS)
- Other (Specify, include date and location)

Date and location of training (Use "Web" for city if web training was received):

Date

City

State

How to submit the Buprenorphine Waiver Notification

- Step 5. Fill out the other areas with the appropriate information and with your preferences.
- Step 6. After submission you might get an error that saying that you did not submit a form showing the CME we completed. This is an autogenerated pop-up created by the website and should be updated shortly.
- Step 7. You should receive approval of your waiver from SAMHSA within 45 days. If not, contact them.

Buprenorphine Waiver Notification

Notification of Intent to Use Schedule III, IV, or V Opioid Drugs for the Maintenance and Detoxification Treatment of Opiate Addiction by a "Qualifying Physician" under 21 USC § 823(g)(2)

Back

SMA-167 Form Approved: 0930-0234

Date: 01/31/2023

See OMB Statement Below

Note: Notification is required by § 303(g)(2), Controlled Substances Act (21 USC § 823(g)(2)). See instructions below.

Your Waiver Notification has been successfully submitted. Please check your spam/junk folders. If you do not see an email attachment in your inbox within 45 days, please contact the Buprenorphine Center at 866-BUP-CSAT (866-287-2728). If you submitted an increase waiver DO NOT send your training certificate. If this is your first time applying and you did not upload your training, please forward via email to CSATBUPInfo@dsgonline.com.

Your waiver has been successfully submitted but there was a problem with one or more of your files and they were not uploaded. Please contact the SAMHSA Center for Substance Abuse Treatment's (CSAT's) Buprenorphine Information Center at 866-BUP-CSAT (866-287-2728) or send an email to infobuprenorphine@samhsa.hhs.gov.

Apply Now

- Submit your notification of Intent : [SAMHSA DATA Waiver](#)
- More information available on the [SAMHSA website](#)
- [Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder](#)